Join the club for FREE to access the whole archive and other member benefits.

Galleri blood test: a step closer to early cancer detection


Key points from article :

A blood test, named the Galleri test, that detects more than 50 types of cancer has shown promise in a major trial conducted by the National Health Service (NHS) in England and Wales.

Among 5,000 participants who exhibited suspected cancer symptoms, the test identified two out of three cancers accurately.

In 85% of positive cases, the test also identified the original cancer site.

The study, the largest of its kind, reported more than 350 participants later diagnosed with cancer using traditional methods; 75% of these had tested positive in the blood test.

Developed by Grail, a Californian company, the test is separately being trialled to detect hidden cancers, in people without symptoms, and is particularly effective at detecting hard-to-spot cancers such as head and neck, bowel, lung, pancreatic, and throat cancers.

Although it is not accurate enough to conclusively confirm or rule out cancer, lead researcher Prof Mark Middleton asserts the test can guide clinicians on which follow-up tests to conduct for a more accurate diagnosis.

Research by Oxford University published in The Lancet Oncology.

Offers promising results in the detection, and original site, of over 50 types of cancer in major NHS study

Mentioned in this article:

Click on resource name for more details.


GRAIL's mission is to detect cancer early, when it can be cured

Mark Middleton

Professor of Experimental Cancer Medicine at the University of Oxford

The Lancet Oncology

Journal providing information relevant to cancer specialists

University of Oxford

Collegiate research university and one of the world's leading universities

Galleri blood test: a step closer to early cancer detection